Funder
PharmaMar SA
European Society for Medical Oncology
Reference18 articles.
1. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial;Goldman;Lancet Oncol,2021
2. Updated overall survival and PD-L1 subgroup Analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133);Liu;J Clin Oncol Off J Am Soc Clin Oncol,2021
3. Nivolumab in pre-treated malignant pleural mesothelioma: real-world data from the Dutch expanded access program;Cantini;Transl Lung Cancer Res,2020
4. Immunotherapy in small cell lung cancer: one step at a time: a narrative review;Dumoulin;Transl Lung Cancer Res,2021
5. Emerging treatments for malignant pleural mesothelioma: where are we heading?;Cantini;Front Oncol,2020
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献